Translational approach for gene therapy in epilepsy: Model system and unilateral overexpression of neuropeptide Y and Y2 receptors

Neurobiology of Disease

Volumn 86, Issue , 2016, Pages 52-61

  Nikitidou Ledri, Litsa ^a   Melin, Esbjörn ^a   Christiansen, Søren H ^b   Gøtzsche, Casper R ^b   Cifra, Alessandra ^a   Woldbye, David P D ^b   Kokaia, Mérab ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adeno associated viral vectors; Gene therapy; Intrahippocampal kainate injection; Neuropeptides; Spontaneous seizures

Indexed keywords

KAINIC ACID; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR; PARVOVIRUS VECTOR; NEUROPEPTIDE Y RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTRODE; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; GENE OVEREXPRESSION; GENE THERAPY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MONITORING; NEUROPEPTIDE Y GENE; NEUROPEPTIDE Y2 RECEPTOR GENE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL; RAT; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; DEPENDOPARVOVIRUS; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; EPILEPSY, TEMPORAL LOBE; GENE VECTOR; GENETICS; PATHOPHYSIOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH; WISTAR RAT;

ANIMALS; CEREBRAL CORTEX; DEPENDOVIRUS; ELECTROENCEPHALOGRAPHY; EPILEPSY, TEMPORAL LOBE; GENETIC THERAPY; GENETIC VECTORS; HIPPOCAMPUS; KAINIC ACID; MALE; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84949034694     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.11.014     Document Type: Article

References (33)

1. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., Palmiter R.D. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1997, 17:8927-8936.
2. Berglund M.M., Hipskind P.A., Gehlert D.R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 2003, 228:217-244.
3. Bragin A., Engel J., Wilson C.L., Vizentin E., Mathern G.W. Electrophysiologic analysis of a chronic seizure model after unilateral hippocampal KA injection. Epilepsia 1999, 40:1210-1221.
4. Brodie M.J., Dichter M.A. Antiepileptic drugs. N. Engl. J. Med. 1996, 334:168-175.
5. Christensen D.Z., Olesen M.V., Kristiansen H., Mikkelsen J.D., Woldbye D.P. Unaltered neuropeptide Y (NPY)-stimulated [35S]GTPgammaS binding suggests a net increase in NPY signalling after repeated electroconvulsive seizures in mice. J. Neurosci. Res. 2006, 84:1282-1291.
6. Decressac M., Barker R.A. Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol. 2012, 238:265-272.
7. Duncan J.S., Sander J.W., Sisodiya S.M., Walker M.C. Adult epilepsy. Lancet 2006, 367:1087-1100.
8. Fernandes de Lima V.M., Pijn J.P., Nunes Filipe C., Lopes da Silva F. The role of hippocampal commissures in the interhemispheric transfer of epileptiform after discharges in the rat: a study using linear and non-linear regression analysis. Electroencephalogr. Clin. Neurophysiol. 1990, 76:520-539.
9. Gotzsche C.R., Nikitidou L., Sorensen A.T., Olesen M.V., Sorensen G., Christiansen S.H., Angehagen M., Woldbye D.P., Kokaia M. Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol. Dis. 2012, 45:288-296.
10. Hanson E.S., Dallman M.F. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J. Neuroendocrinol. 1995, 7:273-279.
11. Heilig M., Thorsell A. Brain neuropeptide Y (NPY) in stress and alcohol dependence. Rev. Neurosci. 2002, 13:85-94.
12. Kalviainen R., Salmenpera T. Do recurrent seizures cause neuronal damage? A series of studies with MRI volumetry in adults with partial epilepsy. Prog. Brain Res. 2002, 135:279-295.
13. Kanter-Schlifke I., Georgievska B., Kirik D., Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol. Ther. 2007, 15:1106-1113.
14. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
15. Kullmann D.M., Schorge S., Walker M.C., Wykes R.C. Gene therapy in epilepsy - is it time for clinical trials?. Nat. Rev. Neurol. 2014, 10:300-304.
16. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
17. McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 2006, 14:63-68.
18. Noe F., Pool A.H., Nissinen J., Gobbi M., Bland R., Rizzi M., Balducci C., Ferraguti F., Sperk G., During M.J., Pitkanen A., Vezzani A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain: A Journal of Neurology 2008, 131:1506-1515.
19. Olesen M.V., Christiansen S.H., Gotzsche C.R., Nikitidou L., Kokaia M., Woldbye D.P. Neuropeptide Y Y1 receptor hippocampal overexpression via viral vectors is associated with modest anxiolytic-like and proconvulsant effects in mice. J. Neurosci. Res. 2012, 90:498-507.
20. Raedt R., Van Dycke A., Van Melkebeke D., De Smedt T., Claeys P., Wyckhuys T., Vonck K., Wadman W., Boon P. Seizures in the intrahippocampal kainic acid epilepsy model: characterization using long-term video-EEG monitoring in the rat. Acta Neurol. Scand. 2009, 119:293-303.
21. Rattka M., Brandt C., Loscher W. The intrahippocampal kainate model of temporal lobe epilepsy revisited: epileptogenesis, behavioral and cognitive alterations, pharmacological response, and hippoccampal damage in epileptic rats. Epilepsy Res. 2013, 103:135-152.
22. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 2002, 71:2921-2937.
23. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2004, 24:3051-3059.
24. Silva A.P., Lourenco J., Xapelli S., Ferreira R., Kristiansen H., Woldbye D.P., Oliveira C.R., Malva J.O. Protein kinase C activity blocks neuropeptide Y-mediated inhibition of glutamate release and contributes to excitability of the hippocampus in status epilepticus. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2007, 21:671-681.
25. Sorensen A.T., Nikitidou L., Ledri M., Lin E.J., During M.J., Kanter-Schlifke I., Kokaia M. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 2009, 215:328-333.
26. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathe A.A., Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12852-12857.
27. Tiesjema B., Adan R.A., Luijendijk M.C., Kalsbeek A., la Fleur S.E. Differential effects of recombinant adeno-associated virus-mediated neuropeptide Y overexpression in the hypothalamic paraventricular nucleus and lateral hypothalamus on feeding behavior. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:14139-14146.
28. Vezzani A., Sperk G., Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999, 22:25-30.
29. Woldbye D.P., Kokaia M. Neuropeptide Y and seizures: effects of exogenously applied ligands. Neuropeptides 2004, 38:253-260.
30. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 1997, 3:761-764.
31. Woldbye D.P., Angehagen M., Gotzsche C.R., Elbrond-Bek H., Sorensen A.T., Christiansen S.H., Olesen M.V., Nikitidou L., Hansen T.V., Kanter-Schlifke I., Kokaia M. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain: A Journal of Neurology 2010, 133:2778-2788.
32. Yilmazer-Hanke D.M., Wolf H.K., Schramm J., Elger C.E., Wiestler O.D., Blümkce I. Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 2000, 59:907-920.
33. Zhou Z., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001.